Arpita Pawashe
A5029431084- Monoclonal and Polyclonal Antibodies Research
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Glycosylation and Glycoproteins Research
- vaccines and immunoinformatics approaches
- Immune Cell Function and Interaction
- Biosimilars and Bioanalytical Methods
- Toxin Mechanisms and Immunotoxins
- Nanowire Synthesis and Applications
Regeneron (United States)
2018-2021
University of Connecticut
2014-2016
The mutational repertoire of cancers creates the neoepitopes that make immunogenic. Here, we introduce two novel tools identify, with relatively high accuracy, small proportion (among hundreds potential neoepitopes) protect host through an antitumor T cell response. consist (a) numerical difference in NetMHC scores between mutated sequences and their unmutated counterparts, termed differential agretopic index, (b) conformational stability MHC I–peptide interaction. Mechanistically, these...
A CD3 bispecific antibody targeting Mucin 16 shows preclinical efficacy in mouse tumor models and a tolerable safety profile nonhuman primates.
CD28 bispecific antibodies are well tolerated and enhance the antitumor efficacy of CD3 bispecifics as a potential off-the-shelf antibody therapy.
Abstract T-cell-redirecting bispecific antibodies have emerged as a new class of therapeutic agents designed to simultaneously bind T cells via CD3 and tumor tumor-cell-specific antigens (TSA), inducing T-cell-mediated killing cells. The promising preclinical clinical efficacy TSAxCD3 is often accompanied by toxicities such cytokine release syndrome due T-cell activation. How the toxicity profile depends on binding affinity remains unclear. Here, we evaluate that were engineered range...
Antibodies cross-linking the CD28 costimulatory pathway and a target antigen on tumors potentiate effects of checkpoint immunotherapy.
Abstract T-cell redirecting bispecific antibodies are an emerging class of therapeutic agents designed to simultaneously bind T cells (via CD3) and tumor cell specific antigens (TSA), with the goal inducing cell-mediated killing cells. Despite promising pre-clinical clinical efficacy from TSAxCD3 antibodies, these have associated toxicities that remain challenging. Here we present findings a series were engineered range CD3 affinities, but which retained same binding affinity selected...
Abstract Advanced ovarian cancer has a high rate of recurrence, thus there is need for therapies that can produce durable responses and extend overall survival. Infiltrating CD3+ T cells are reported to correlate with improved clinical outcome in stage III/IV cancer. Bispecific antibodies engage via CD3 tumor antigen on may be able exploit these tumor-infiltrating have drawn interest as novel strategy antitumor immunotherapy. Mucin16 (MUC16) well described highly expressed several other...